BASI vs. DKDCA, LUNA, BIAF, AIKI, NOTV, AVRO, FIXX, ELDN, GANX, and ABIO
Should you be buying Bioanalytical Systems stock or one of its competitors? The main competitors of Bioanalytical Systems include Data Knights Acquisition (DKDCA), Luna Innovations (LUNA), bioAffinity Technologies (BIAF), AIkido Pharma (AIKI), Inotiv (NOTV), AVROBIO (AVRO), Homology Medicines (FIXX), Eledon Pharmaceuticals (ELDN), Gain Therapeutics (GANX), and ARCA biopharma (ABIO).
Bioanalytical Systems (NASDAQ:BASI) and Data Knights Acquisition (NASDAQ:DKDCA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.
In the previous week, Data Knights Acquisition had 2 more articles in the media than Bioanalytical Systems. MarketBeat recorded 2 mentions for Data Knights Acquisition and 0 mentions for Bioanalytical Systems. Bioanalytical Systems' average media sentiment score of 0.00 equaled Data Knights Acquisition'saverage media sentiment score.
10.6% of Bioanalytical Systems shares are owned by institutional investors. Comparatively, 35.3% of Data Knights Acquisition shares are owned by institutional investors. 11.5% of Bioanalytical Systems shares are owned by insiders. Comparatively, 45.7% of Data Knights Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Data Knights Acquisition has a net margin of 0.00% compared to Bioanalytical Systems' net margin of -7.75%. Data Knights Acquisition's return on equity of 0.00% beat Bioanalytical Systems' return on equity.
Bioanalytical Systems received 128 more outperform votes than Data Knights Acquisition when rated by MarketBeat users.
Bioanalytical Systems has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Comparatively, Data Knights Acquisition has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500.
Data Knights Acquisition has lower revenue, but higher earnings than Bioanalytical Systems. Bioanalytical Systems is trading at a lower price-to-earnings ratio than Data Knights Acquisition, indicating that it is currently the more affordable of the two stocks.
Summary
Data Knights Acquisition beats Bioanalytical Systems on 9 of the 12 factors compared between the two stocks.
Get Bioanalytical Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for BASI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bioanalytical Systems Competitors List
Related Companies and Tools
